We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Diovan (valsartan)

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Diovan (valsartan)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Diovan, in both capsule and tablet formulations, has been approved for the treatment of hypertension in adult subjects. It offers blood pressure control comparable to current leading antihypertensive therapies (lisinopril and enalapril) and an outstanding side effect profile.

    As with other drugs that affect the renin-angiotensin system, Diovan can cause fetal and neonatal morbidity and death when administered to pregnant women. Diovan therapy should be discontinued as soon as pregnancy is detected.

    Hypertension, the term used for abnormally high blood pressure, is the most common health problem in the United States. Over 50 million Americans suffer from hypertension, but many are unaware of the problem and remain untreated. Left untreated, it can lead to serious and life-threatening events including stroke and heart attack.

    Clinical Results

    Diovan capsules were evaluated in seven placebo-controlled, four to 12 week trials in adult subjects with baseline diastolic blood pressures of 95-115. One trial included subjects over the age of 65. In total, over 2000 subjects were randomized to various doses of the drug and about 800 were treated with placebo.

    Results indicated that administration of Diovan to hypertensive subjects led to a significant decrease in sitting, supine, and standing systolic and diastolic blood pressure, usually with little or no orthostatic change.

    Side Effects

    Adverse events associated with the use of Diovan capsules and tablets may include (but are not limited to) the following:


    • Headache
    • Dizziness
    • Viral infection
    • Fatigue
    • Abdominal pain

    Warning - Diovan should not be taken during pregnancy.

    Mechanism of Action

    Diovan (valsartan) blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues. Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects including vasocantstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.

    Additional Information

    For additional information on Diovan, please visit Diovan.

    Date Created: 2001-08-23 12:00:00
    Company Name: Novartis
    Back to Listings

    Upcoming Events

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    • China-360x240

      U.S. Tops List of Trial Startups With China Making Progress in Phase 1

    • Phoneapp-360x240

      Device Apps Present Unique Risks in Trials

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing